ATE246937T1 - Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff - Google Patents

Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff

Info

Publication number: ATE246937T1
Authority: AT; Austria
Prior art keywords: liquid vaccine; threalose; stabilization; vaccine composition; liquid
Prior art date: 1999-03-23

Application number

AT00912734T

Other languages

English (en)

Inventor

Graf Sandrine Lentsch

Jean-Rene Cartier

Original Assignee

Aventis Pasteur

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-23

Filing date

2000-03-23

Publication date

2003-08-15

2000-03-23 Application filed by Aventis Pasteur filed Critical Aventis Pasteur

2003-08-15 Application granted granted Critical

2003-08-15 Publication of ATE246937T1 publication Critical patent/ATE246937T1/de

Links

229960005486 vaccine Drugs 0.000 title abstract 4
239000007788 liquid Substances 0.000 title abstract 3
230000006641 stabilisation Effects 0.000 title 1
238000011105 stabilization Methods 0.000 title 1
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 2
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 2
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 2
102000014914 Carrier Proteins Human genes 0.000 abstract 1
108010078791 Carrier Proteins Proteins 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
150000004676 glycans Chemical class 0.000 abstract 1
229920001282 polysaccharide Polymers 0.000 abstract 1
239000005017 polysaccharide Substances 0.000 abstract 1
230000003019 stabilising effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Microbiology (AREA)
Dermatology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AT00912734T 1999-03-23 2000-03-23 Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff ATE246937T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9903765A FR2791895B1 (fr)	1999-03-23	1999-03-23	Utilisation de trehalose pour stabiliser un vaccin liquide
PCT/FR2000/000730 WO2000056365A1 (fr)	1999-03-23	2000-03-23	Utilisation de trehalose pour stabiliser un vaccin liquide

Publications (1)

Publication Number	Publication Date
ATE246937T1 true ATE246937T1 (de)	2003-08-15

Family

ID=9543654

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00912734T ATE246937T1 (de)	1999-03-23	2000-03-23	Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff

Country Status (11)

Country	Link
EP (1)	EP1163008B1 (de)
JP (1)	JP2002540079A (de)
AT (1)	ATE246937T1 (de)
AU (1)	AU3438900A (de)
CA (1)	CA2366869A1 (de)
DE (1)	DE60004496T2 (de)
DK (1)	DK1163008T3 (de)
ES (1)	ES2200845T3 (de)
FR (1)	FR2791895B1 (de)
PT (1)	PT1163008E (de)
WO (1)	WO2000056365A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2324093A (en)	1996-01-04	1998-10-14	Rican Limited	Helicobacter pylori bacterioferritin
GB0115176D0 (en)	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en)	2001-09-06	2001-10-24	Chiron Spa	Hybrid and tandem expression of neisserial proteins
HUE031886T2 (en)	2002-10-11	2017-08-28	Glaxosmithkline Biologicals Sa	Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
EP2172213B1 (de)	2003-01-30	2013-04-03	Novartis AG	Injizierbarer Impfstoff gegen multiple Meningokokken-Serogruppen
GB0323103D0 (en)	2003-10-02	2003-11-05	Chiron Srl	De-acetylated saccharides
NZ546430A (en)	2003-10-02	2009-04-30	Novartis Vaccines & Diagnostic	Liquid vaccines for multiple meningococcal serogroups
GB0406013D0 (en)	2004-03-17	2004-04-21	Chiron Srl	Analysis of saccharide vaccines without interference
MX2008014391A (es) *	2006-05-12	2009-03-06	Bharat Biotech Int Ltd	Una composicion util como vacuna.
JP5814507B2 (ja)	2006-09-07	2015-11-17	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
JP2010525035A (ja)	2007-05-02	2010-07-22	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
PL2198007T3 (pl)	2007-09-14	2018-03-30	Sanofi Pasteur Biologics, Llc	Kompozycje farmaceutyczne zawierające toksoidy A i B Clostridium difficile
EP2106788A1 (de)	2008-04-04	2009-10-07	Ipsen Pharma	Flüssige und lyophilisierte Formulierungen
BR112012009014B8 (pt)	2009-09-30	2022-10-04	Novartis Ag	Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica
CA2792687A1 (en)	2010-03-10	2011-09-15	Glaxosmithkline Biologicals S.A.	Immunogenic composition
GB201101665D0 (en)	2011-01-31	2011-03-16	Novartis Ag	Immunogenic compositions
GB201016969D0 (en)	2010-10-08	2010-11-24	Genome Res Ltd	Expression system
EP2524701A3 (de)	2011-05-20	2012-12-19	Nitto Denko Corporation	Pharmazeutische Zusammensetzung und Herstellungsverfahren dafür
US9358284B2 (en)	2011-09-14	2016-06-07	Glaxosmithkline Biologicals Sa	Methods for making saccharide-protein glycoconjugates
WO2013083753A2 (en)	2011-12-07	2013-06-13	Institut Pasteur	Identification of a swine parecho-like virus and applications
RU2014151567A (ru)	2012-05-22	2016-07-10	Новартис Аг	Конъюгат менингококка серогруппы х
FR2992656B1 (fr) *	2012-07-02	2016-10-07	Sanofi Pasteur	Procede de production d'antigenes haemophilus influenzae type b
CN104487086B (zh) *	2012-07-07	2019-08-30	巴拉特生物技术国际有限公司	无动物源的不含酒精的疫苗组合物及其制备方法
RU2015106791A (ru)	2012-10-03	2016-11-20	Глэксосмитиклайн Байолоджикалз Са	Иммуногенные композиции
SI3421997T1 (sl) *	2012-12-28	2020-10-30	Cellestis Limited	Test celično posredovanega imunskega odziva
BE1024634B1 (fr)	2016-04-05	2018-05-14	Gsk Vaccines S.R.L.	Compositions immunogenes
BR112019003992A2 (pt)	2016-09-02	2019-05-28	Sanofi Pasteur Inc	vacina contra neisseria meningitidis
US11149255B2 (en)	2016-09-06	2021-10-19	Bioventures, Llc	Compositions and methods for generating reversion free attenuated and/or replication incompetent vaccine vectors
US12544441B2 (en)	2016-11-01	2026-02-10	Washington University	Compositions comprising CelTOS immunogens and antibodies and method of use thereof
US12398184B2 (en)	2016-11-01	2025-08-26	Washington University	Compositions comprising CelTOS immunogens and antibodies and method of use thereof
CN110651189B (zh)	2017-03-03	2024-10-25	特雷斯生物有限公司	肽疫苗
EP3369431A1 (de)	2017-03-03	2018-09-05	Treos Bio Kft	Impfstoff
EP3370065A1 (de)	2017-03-03	2018-09-05	Treos Bio Kft	Immunogene peptide
GB201814362D0 (en)	2018-09-04	2018-10-17	Treos Bio Zrt	Composition and process for preparing vaccine
JP7642530B2 (ja)	2018-09-04	2025-03-10	トレオスバイオリミテッド	ペプチドワクチン
IL282753B2 (en)	2018-11-06	2025-04-01	Glaxosmithkline Biologicals Sa	Immunogenic compounds
GB201908332D0 (en)	2019-06-11	2019-07-24	Univ Oxford Innovation Ltd	Assays and inhibitors of oxygen-dependent N-terminal oxidation
EP4126027A1 (de)	2020-04-03	2023-02-08	PepTC Vaccines Limited	Coronavirus-impfstoff
GB202004974D0 (en)	2020-04-03	2020-05-20	Treos Bio Ltd	Coronavirus vaccine
WO2022268916A2 (en)	2021-06-23	2022-12-29	Ose Immunotherapeutics	Pan-coronavirus peptide vaccine
GB202109082D0 (en)	2021-06-24	2021-08-11	Univ Oxford Innovation Ltd	Polypeptides and uses thereof
WO2023148333A1 (en)	2022-02-03	2023-08-10	CeCaVa GmbH & Co. KG	Co-vaccination with cd4 and cd8 antigens
GB202208695D0 (en)	2022-06-14	2022-07-27	Univ Oxford Innovation Ltd	Antibacterials

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2748132A1 (de) *	1977-10-27	1979-05-03	Behringwerke Ag	Stabilisator fuer polysaccharid
US4902506A (en) *	1983-07-05	1990-02-20	The University Of Rochester	Immunogenic conjugates
IL78775A (en) *	1985-05-15	1992-06-21	Biotech Australia Pty Ltd	Oral vaccines
DE69419966T2 (de) *	1993-05-17	2000-01-20	Akzo Nobel N.V., Arnheim/Arnhem	Impstoff gegen Streptococcus suis-Infektion
DE69530196T2 (de) *	1994-06-02	2003-11-20	Elan Drug Delivery Ltd	Methode zum verhindern der aggregation von proteinen/peptiden bei rehydratation oder auftauen
WO1998013065A1 (en) *	1996-09-26	1998-04-02	Merck & Co., Inc.	Rotavirus vaccine formulations
US6210683B1 (en) *	1997-09-05	2001-04-03	Merck & Co., Inc.	Stabilizers containing recombinant human serum albumin for live virus vaccines

1999
- 1999-03-23 FR FR9903765A patent/FR2791895B1/fr not_active Expired - Fee Related
2000
- 2000-03-23 AU AU34389/00A patent/AU3438900A/en not_active Abandoned
- 2000-03-23 DK DK00912734T patent/DK1163008T3/da active
- 2000-03-23 PT PT00912734T patent/PT1163008E/pt unknown
- 2000-03-23 EP EP00912734A patent/EP1163008B1/de not_active Expired - Lifetime
- 2000-03-23 CA CA002366869A patent/CA2366869A1/en not_active Abandoned
- 2000-03-23 JP JP2000606269A patent/JP2002540079A/ja active Pending
- 2000-03-23 ES ES00912734T patent/ES2200845T3/es not_active Expired - Lifetime
- 2000-03-23 AT AT00912734T patent/ATE246937T1/de not_active IP Right Cessation
- 2000-03-23 WO PCT/FR2000/000730 patent/WO2000056365A1/fr not_active Ceased
- 2000-03-23 DE DE60004496T patent/DE60004496T2/de not_active Expired - Fee Related

Also Published As

Publication number	Publication date
FR2791895B1 (fr)	2001-06-15
CA2366869A1 (en)	2000-09-28
DK1163008T3 (da)	2003-11-17
PT1163008E (pt)	2003-12-31
FR2791895A1 (fr)	2000-10-13
EP1163008A1 (de)	2001-12-19
DE60004496D1 (de)	2003-09-18
AU3438900A (en)	2000-10-09
JP2002540079A (ja)	2002-11-26
DE60004496T2 (de)	2004-04-08
EP1163008B1 (de)	2003-08-13
WO2000056365A1 (fr)	2000-09-28
ES2200845T3 (es)	2004-03-16

Legal Events

Date

Code

Title

Description

2003-12-15

UEP

Publication of translation of european patent specification

Ref document number: 1163008

Country of ref document: EP

2009-12-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE246937T1 (de)	2003-08-15	Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff
UA93855C2 (ru)	2011-03-25	Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
IL210392A0 (en)	2011-03-31	Antibodies that bind to tgf-?? binding proteins with an affinity of 106m-1 and uses thereof
DE69819332D1 (de)	2003-12-04	VERBESSERTE ANTIKÖRPER GEGEN IgE UND VERFAHREN ZUR VERBESSERUNG VON ANTIKÖRPERN
DE60100473D1 (de)	2003-08-21	Verwendung von neurotoxinen in medikamenten zur behandlung von thyroidstörungen
DE69936948D1 (de)	2007-10-04	Virusenthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten
ATE394536T1 (de)	2008-05-15	Textilweichmacherzusammensetzungen und verfahren zur stabilisierung von textilweichmacherzusammensetzungen
YU9404A (sh)	2006-08-17	Multimerna, usmerena kontrastna sredstva na bazi peptida
DE60018907D1 (de)	2005-04-28	Verfahren und zusammensetzung zur zementierung von bohrlöchern
DE60116322D1 (de)	2006-02-02	Vorrichtung zur aktiven kompensation von aberrationen in einem optischen system
DE69833134D1 (de)	2006-03-30	Verwendung aliphatischer amine zur verminderung von oxalat
DE60229059D1 (de)	2008-11-06	Proteomimetische verbindungen und verfahren
DE69717413D1 (de)	2003-01-09	Verfahren zur Gewichtsbestimmung von bogenförmigen Trägern
ATE257482T1 (de)	2004-01-15	Verfahren zur stabilisierung von siloxan- verbindungen
ATE220558T1 (de)	2002-08-15	Verbessertes verfahren zur stabilisierung von proteinen
MY150893A (en)	2014-03-14	Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
DE60230456D1 (de)	2009-01-29	Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
ATE338814T1 (de)	2006-09-15	Verfahren zur kultivierung von zellen und zur vermehrung von viren
DE69823711D1 (de)	2004-06-17	Verfahren zur Stabilisierung von Siloxanpolymeren
ATE424217T1 (de)	2009-03-15	Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
EP1075184A4 (de)	2002-01-30	Zusammensetzungen und verfahren zur aktiven impfung
ATE274185T1 (de)	2004-09-15	Verfahren und zusammensetzungen zur trennung von biologischen makromolekülen
ATE489466T1 (de)	2010-12-15	Nukleinsäuren zur hemmung der expression von hairless-protein und verfahren zur verwendung davon
DE69830156D1 (de)	2005-06-16	Zusammensetzungen zur immunverstärkung von impfstoffen
WO2002062964A3 (en)	2007-08-02	Ap1 amine oxidase variants